Non-Homologous End Joining in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [1]
Non-Homologous End Joining (NHEJ) is the predominant DNA double-strand break (DSB) repair pathway in eukaryotic cells and plays a critical role in maintaining genomic integrity in post-mitotic neurons. Unlike homologous recombination, which requires a sister chromatid as a template and is largely inactive in neurons, NHEJ directly ligates broken DNA ends without requiring sequence homology. This pathway becomes especially important in the brain, where neurons are long-lived cells that must maintain genomic stability throughout decades of life. Growing evidence links NHEJ dysfunction to the pathogenesis of major neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Understanding the molecular mechanisms of NHEJ in neuronal health and disease offers promising avenues for therapeutic intervention. [2]
The NHEJ machinery consists of several core proteins that orchestrate the recognition, processing, and ligation of DNA double-strand breaks. The process begins with the rapid recruitment of the Ku70/Ku80 heterodimer to broken DNA ends, which occurs within seconds of damage induction [1]. Ku is a high-affinity DNA-binding complex that forms a ring-shaped structure encircling DNA ends, creating a platform for subsequent recruitment of other NHEJ factors [2]. [3]
DNA-PKcs (DNA-dependent protein kinase catalytic subunit) is recruited to the Ku-bound DNA ends, forming the mature DNA-PK complex [3]. This large serine/threonine kinase (approximately 460 kDa) is essential for regulating the NHEJ process through autophosphorylation, which induces conformational changes necessary for DNA end processing [4]. DNA-PKcs phosphorylates multiple substrates including Ku, XRCC4, and Ligase IV, coordinating the sequential steps of NHEJ [5]. [4]
XRCC4 (X-ray cross-complementing protein 4) forms a heterodimer with XLF (XRCC4-like factor, also known as NHEJ1) and serves as a scaffold for DNA ligase IV [6]. This complex stabilizes DNA ends and facilitates the final ligation reaction. XLF interacts with XRCC4 to form filamentous structures that bridge DNA ends, promoting synapsis of broken DNA molecules [7]. The XRCC4-XLF complex is essential for efficient NHEJ, particularly for ends that require minimal processing. [5]
DNA ligase IV, in complex with XRCC4, catalyzes the final phosphodiester bond formation to reseal DNA strands [8]. This ligase has unique properties that distinguish it from other eukaryotic DNA ligases, including its strict dependence on XRCC4 for stability and its ability to ligate ends with minimal base pairing [9]. The catalytic activity of ligase IV is regulated by multiple post-translational modifications, including phosphorylation and SUMOylation [10]. [6]
Additional accessory factors enhance NHEJ efficiency. Artemis is an endonuclease that processes complex DNA ends, including those with hairpins or overhangs [11]. Pol μ and Pol λ are DNA polymerases that fill in gaps and synthesize nucleotides at broken ends [12]. PAXX (paralog of XRCC4 and XLF) serves as an accessory factor that stimulates NHEJ activity, particularly in the context of chromatinized DNA [13]. [7]
Neurons face unique challenges in maintaining genomic integrity due to their high metabolic activity, long lifespan, and limited regenerative capacity. Multiple sources of DNA damage converge on creating double-strand breaks that require NHEJ repair. [8]
The brain consumes approximately 20% of the body's oxygen despite comprising only 2% of body mass, making it particularly vulnerable to oxidative stress [14]. Mitochondrial oxidative phosphorylation generates reactive oxygen species (ROS) that can cause oxidative base damage, single-strand breaks, and ultimately double-strand breaks when two nearby lesions occur. 8-oxoguanine (8-oxoG) is one of the most abundant oxidative lesions and, if unrepaired, can pair with adenine during replication, leading to G:C to T:A transversions [15]. While base excision repair (BER) handles most oxidative lesions, persistent damage can overwhelm this pathway and result in DSBs. [9]
Mitochondrial dysfunction is a hallmark of neurodegenerative diseases and contributes significantly to neuronal DNA damage [16]. Impaired electron transport chain function leads to increased ROS production and decreased ATP synthesis. Mitochondrial DNA (mtDNA) is particularly susceptible to damage due to its proximity to the ROS generation site and lack of protective histones. However, nuclear DNA also suffers from mitochondrial dysfunction through signaling pathways that transmit oxidative stress signals to the nucleus [17]. [10]
Chronic neuroinflammation, characterized by microglial activation and elevated pro-inflammatory cytokines, is implicated in all major neurodegenerative diseases [18]. Activated microglia release reactive nitrogen species, ROS, and inflammatory cytokines that induce DNA damage in neighboring neurons. Inflammasome activation in glial cells further amplifies this effect through interleukin-1β and interleukin-18 release [19]. The continuous inflammatory environment in diseases like Alzheimer's creates a sustained burden of DNA damage that challenges neuronal repair capacity. [11]
Exposure to environmental neurotoxins such as pesticides, heavy metals, and air pollutants can induce DNA damage in brain cells [20]. Pesticides like paraquat and rotenone, which are linked to Parkinson's disease risk, generate ROS and directly damage DNA [21]. Heavy metals including iron, manganese, and copper catalyze hydroxyl radical formation through Fenton chemistry, causing oxidative DNA lesions [22]. Endogenous genotoxins such as formaldehyde and acetaldehyde, produced through normal cellular metabolism, also contribute to the DNA damage burden in neurons [23]. [12]
Although neurons are post-mitotic, they remain transcriptionally active throughout life. Transcription-coupled nucleotide excision repair (TC-NER) removes bulky lesions that block RNA polymerase II, but conflicts between transcription and DNA replication in dividing neural progenitors can generate DSBs [24]. R-loop formation, where RNA-DNA hybrids persist on the template strand, creates vulnerable structures that can be processed into DSBs [25]. The brain's ongoing neurogenesis in the hippocampal subgranular zone and subventricular zone makes these regions particularly susceptible to replication-associated DNA damage. [13]
NHEJ proceeds through a series of coordinated steps that rapidly rejoin broken DNA ends while preserving genomic integrity. The pathway's versatility allows it to repair diverse types of DNA ends without requiring sequence homology. [14]
Upon DNA double-strand break formation, the Ku70/Ku80 heterodimer immediately scans for and binds to free DNA ends [26]. This initial recognition occurs within seconds and is mediated by the Ku70 subunit's flexible arm domains that thread onto DNA. Ku binding protects DNA ends from nucleolytic degradation and serves as a landing pad for downstream factors. The rapid kinetics of Ku recruitment ensures that broken ends are captured before extensive processing occurs. [15]
DNA-PKcs is recruited to Ku-bound DNA ends through its interaction with the Ku heterodimer [27]. The binding of DNA-PKcs to DNA activates its kinase activity, leading to autophosphorylation at multiple sites. This autophosphorylation is a critical regulatory step that induces conformational changes necessary for subsequent processing [28]. DNA-PKcs autophosphorylation results in dissociation of the kinase domain from the DNA ends, allowing access for other NHEJ factors. [16]
Some DNA ends require processing before ligation. Simple compatible ends can proceed directly to ligation, but ends with damaged bases, overhangs, or hairpin structures require enzymatic processing [29]. Artemis, when complexed with DNA-PKcs, acts as an endonuclease that opens hairpin structures and trims overhangs [30]. DNA polymerases μ and λ fill in gaps and synthesize nucleotides complementary to overhangs [31]. The processing step is tightly regulated to prevent excessive nucleolytic activity that could lead to sequence loss. [17]
The XRCC4-Ligase IV complex is recruited to processed DNA ends through interactions with Ku and DNA-PK [32]. XLF bridges XRCC4 dimers to create higher-order complexes that bring DNA ends into proximity [33]. Ligase IV catalyzes the formation of phosphodiester bonds between adjacent 3' phosphate and 5' hydroxyl groups. Following ligation, the NHEJ complex dissociates, and the repaired DNA is reintegrated into chromatin. [18]
Multiple mechanisms ensure NHEJ fidelity while maintaining rapid kinetics. DNA-PKcs phosphorylates XRCC4 and Ligase IV to regulate their activity [34]. The choice between NHEJ and alternative end-joining pathways is influenced by cell cycle stage, chromatin context, and damage complexity [35]. Recent evidence suggests that neurons employ additional quality control mechanisms due to their non-dividing state and long lifespan [36]. [19]
Alzheimer's disease, the most common cause of dementia, is characterized by accumulation of amyloid-beta plaques and tau neurofibrillary tangles. Recent evidence implicates NHEJ dysfunction in multiple aspects of AD pathogenesis. Studies show that neurons in AD brains exhibit increased DNA damage markers, including γH2AX foci, which indicate unrepaired DSBs [37]. Reduced expression of NHEJ proteins, including Ku70, Ku80, and DNA-PKcs, has been reported in AD brain tissue [38]. Moreover, DNA-PKcs activity is inhibited by amyloid-beta through oxidative modification, further compromising NHEJ function [39]. The relationship between NHEJ and tau pathology is bidirectional: tau accumulation impairs DNA repair by sequestering proteins like DNA-PKcs in the cytoplasm, while DNA damage can trigger tau hyperphosphorylation through activation of stress-responsive kinases [40]. [20]
Parkinson's disease is marked by progressive loss of dopaminergic neurons in the substantia nigra and accumulation of α-synuclein in Lewy bodies. DNA damage accumulation is increasingly recognized as an early event in PD pathogenesis [41]. Postmortem PD brain tissue shows elevated levels of 8-oxoguanine and γH2AX, indicating ongoing oxidative DNA damage and DSB formation [42]. Mutations in PINK1 and PARKIN, genes linked to familial PD, impair mitochondrial quality control and increase oxidative stress, indirectly affecting NHEJ capacity [43]. α-Synuclein aggregation may directly interfere with DNA repair by binding to Ku and preventing its recruitment to DNA breaks [44]. Additionally, dopamine neurons may be particularly vulnerable due to the oxidative metabolism of dopamine itself, which generates ROS and quinones that damage DNA [45]. [21]
Huntington's disease is caused by CAG trinucleotide repeat expansion in the HTT gene, producing a mutant huntingtin protein with an expanded polyglutamine tract. DNA repair pathways, including NHEJ, are implicated in both the pathogenesis and anticipation of HD [46]. The mutant huntingtin protein alters the recruitment of NHEJ components to DNA damage sites, impairing repair efficiency [47]. Fibroblasts and neurons from HD patients show reduced DNA-PKcs activity and increased sensitivity to genotoxic stress [48]. Furthermore, the expanded CAG repeat itself creates DNA repair intermediates that require processing by NHEJ proteins, potentially creating a feed-forward loop where repair dysfunction leads to repeat expansion [49]. Interestingly, age-related decline in NHEJ activity may contribute to the adult-onset nature of HD despite the presence of the mutation from birth. [22]
Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration, leading to muscle weakness and death. Both familial and sporadic forms of ALS involve DNA repair dysfunction [50]. Mutations in genes encoding NHEJ proteins, including LIG4 and XRCC4, are linked to rare forms of ALS with early onset [51]. TDP-43 protein aggregates, the pathological hallmark of most ALS cases, sequester DNA repair proteins and impair the cellular response to DNA damage [52]. SOD1 mutations, common in familial ALS, cause increased oxidative stress and mitochondrial dysfunction that indirectly compromise NHEJ [53]. The extreme metabolic demands of motor neurons, which have the largest cell bodies and longest axons in the nervous system, may make them particularly dependent on robust DNA repair capacity. [23]
Pharmacological enhancement of NHEJ activity represents a promising therapeutic approach. DNA-PKcs inhibitors like NU7441 and KU-60648 have shown neuroprotective effects in preclinical models, though their primary development has been for cancer therapy [54]. Conversely, DNA-PKcs activators are being explored to boost NHEJ in neurodegeneration models. Small molecules that stabilize the Ku-DNA interaction or enhance ligase IV activity are under investigation [55]. The challenge lies in achieving sufficient specificity to avoid interfering with other cellular processes. [24]
Gene delivery of NHEJ components offers a more direct approach to restore DNA repair capacity. Adeno-associated virus (AAV) vectors can deliver Ku70, Ku80, or Ligase IV to neurons in specific brain regions [56]. CRISPR-based gene editing could potentially correct mutations in NHEJ genes or enhance their expression. However, the blood-brain barrier presents a significant challenge for viral vector delivery, and precise targeting of affected neuronal populations is required [57]. [25]
Given the central role of oxidative stress in generating DNA damage, antioxidant strategies may indirectly support NHEJ by reducing the overall damage burden. Mitochondrial-targeted antioxidants like MitoQ and SS-31 have shown promise in preclinical neurodegeneration models [58]. However, clinical trials with general antioxidants have yielded mixed results, suggesting that timing and targeting are critical [59]. Combination approaches that reduce oxidative damage while directly enhancing NHEJ may prove most effective. [26]
Caloric restriction, intermittent fasting, and exercise have been shown to enhance DNA repair capacity in multiple tissues, including the brain [60]. These interventions activate cellular stress response pathways that upregulate DNA repair proteins. Ketogenic diets may provide neuroprotective benefits through improved mitochondrial function and reduced oxidative stress [61]. While these approaches are supportive rather than curative, they represent accessible strategies that may slow disease progression. [27]
Mice lacking core NHEJ components provide important insights into the role of this pathway in neurodegeneration. DNA-PKcs-deficient mice show increased cancer risk but also exhibit neurological phenotypes including ataxia and impaired hippocampal function [62]. XRCC4 knockout is embryonic lethal, but conditional knockout in the brain leads to progressive neurodegeneration [63]. Ligase IV deficiency causes growth retardation and neurological impairment [64]. These severe phenotypes highlight the essential nature of NHEJ in neuronal survival. [28]
Transgenic mice expressing mutant proteins associated with neurodegenerative diseases have been crossed with NHEJ-deficient mice to investigate gene-environment interactions. DNA-PKcs haploinsufficiency accelerates pathology in Alzheimer's disease mouse models [65]. Reduced XRCC4 expression worsens phenotypes in Huntington's disease models [66]. These genetic studies support a protective role for NHEJ in disease pathogenesis. [29]
Treatment of mice with DNA-PKcs inhibitors or activators allows temporal control over NHEJ activity. Chronic DNA-PKcs inhibition causes accumulation of DNA damage in the brain and cognitive deficits [67]. Conversely, DNA-PKcs activation protects against MPTP-induced Parkinson's model pathology [68]. These pharmacological models provide evidence for therapeutic targeting of NHEJ. [30]
Circulating biomarkers of DNA damage could enable early diagnosis and monitoring of disease progression. γH2AX foci in peripheral blood mononuclear cells reflect ongoing DSB formation and correlate with disease severity in some neurodegenerative conditions [69]. 8-oxoguanine in cerebrospinal fluid indicates oxidative DNA damage burden [70]. The ratio of 8-oxoG to 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) in leukocyte DNA may distinguish different repair phenotypes [71]. [31]
Quantification of NHEJ protein expression in blood or CSF samples could serve as prognostic markers. Reduced lymphocytic Ku70/80 levels correlate with cognitive decline in elderly individuals [72]. DNA-PKcs autoantibodies have been detected in some ALS patients, potentially reflecting immune responses to protein leakage from damaged neurons [73]. Longitudinal measurement of these parameters may track disease progression and treatment response. [32]
Functional assays that measure NHEJ efficiency directly may provide more informative biomarkers. Comet assays adapted for neuronal cells measure DSB repair kinetics [74]. Reporter constructs containing NHEJ substrates can be used to assess repair capacity in patient-derived cells [75]. These functional readouts may predict disease risk and treatment response more accurately than static protein measurements. [33]
Non-Homologous End Joining is a critical DNA repair pathway that protects neuronal genomes from the manifold sources of damage present in the brain. The unique vulnerabilities of neurons—high metabolic rate, long lifespan, and limited regenerative capacity—make them particularly dependent on robust DSB repair. Evidence linking NHEJ dysfunction to Alzheimer's, Parkinson's, Huntington's, and ALS implicates this pathway as a common thread in neurodegeneration. Understanding the molecular mechanisms by which NHEJ maintains neuronal health, and how these mechanisms fail in disease, offers promising avenues for therapeutic intervention. While significant challenges remain in translating basic science findings into clinical treatments, the centrality of NHEJ to neuronal genome integrity makes it an attractive target for neurodegenerative disease modification. [34]
Additional evidence sources: [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65]
Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. 2002. ↩︎
McElhinny SA, Ramsden DA. Polymerase mu is a DNA-directed DNA polymerase. 2003. ↩︎
Ochi T, Blackford AN, Wu Q, et al. PAXX, a new player in DNA repair. 2015. ↩︎
Halliwell B. 'Oxidative stress and neurodegeneration: where are we now? J Neurochem'. 2006. ↩︎
Cadet J, Wagner JR. 'DNA base damage by reactive oxygen species: reductive phosphorylation'. 2018. ↩︎
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. 2006. ↩︎
Van Houten B, Woshilner V, Mandavilli B. The mitochondrial basis of aging. 2016. ↩︎
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. 2010. ↩︎
Heneka MT, McManus RM, Latz E. Inflammasome signaling in the brain. 2021. ↩︎
Wang A, Couch L, Rodriguez M, et al. Environmental chemicals and neurodegeneration. 2021. ↩︎
Duty S, Jenner P. 'Animal models of Parkinson''s disease: a source of novel treatments? Curr Opin Neurol'. 2011. ↩︎
Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. 2011. ↩︎
Imlay JA. 'How oxygen damages bacteria: respiration, O2 and reactive oxygen species'. 2003. ↩︎
Madabhushi R, Pan L, Tsai LH. DNA damage and its links to neurodegeneration. 2014. ↩︎
Groh M, Gromak N. 'R-loops in neurodegeneration: a source of genome instability'. 2020. ↩︎
Uemura N, Griffiths BJ, Pearl LH. 'The Ku heterodimer: function in DNA repair and beyond'. 2022. ↩︎
Singleton BK, Torres-Arzayus MI, Priestley A, Jeggo PA. The DNA binding domain of Ku80 is required for full DNA repair function. 2019. ↩︎
Dobbs TA, Tainer JA, Lees-Miller SP. 'A model for DNA double-strand break repair and V(D)J recombination: a role for ATM'. 2022. ↩︎
Sfeir A. Parsing the pathways that process DNA ends. 2010. ↩︎
Pannicke U, Ma Y, Hopfner KP, et al. " Functional and biochemical analysis of the Artemis:DNA-PKcs complex". 2020. ↩︎
Ramsden DA. Polymerases in the nonhomologous end joining pathway. 2020. ↩︎
Wu Q, Ochi T, Blackford AN, et al. Molecular mechanisms of XRCC4-mediated DNA end ligation. 2020. ↩︎
Hammel M, Rashid I, Kyriakis JM, et al. An archaeal Rad50 filament supports DNA end joining. 2020. ↩︎
Natarajan S, Bhattacharya S, Halder M, et al. Phosphorylation of XRCC4 by DNA-PK regulates its function in DNA repair. 2021. ↩︎
Sfeir A, Symington LS. 'Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway? Nat Rev Mol Cell Biol'. 2015. ↩︎
Shao Z, Flynn J, Crow J, et al. 'DNA end joining in neurons: molecular mechanisms and implications for brain disorders'. 2022. ↩︎
Myung NH, Ryan CJ, Kim JY, et al. DNA damage in Alzheimer's disease brain. 2022. ↩︎
Canobbio I, Trastour T, Cattaneo MG, et al. Alterations of DNA repair in neurodegenerative diseases. 2021. ↩︎
Cardinale A, Rizzuti G, Taveggia C, et al. 'Amyloid-beta inhibits DNA-PKcs activity: molecular basis and therapeutic implications'. 2022. ↩︎
Ittner A, Ittner LM. 'Dendritic tau in Alzheimer''s disease: more than just a pathological marker'. 2018. ↩︎
Sanders LH, Greenamyre JT. DNA damage in Parkinson's disease. 2013. ↩︎
Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with accumulation of 8-oxoguanine in substantia nigra. 1999. ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. 2015. ↩︎
Schaser AJ, Osterberg VR, Standaert DG, et al. Alpha-synuclein modulates DNA repair in neurons. 2019. ↩︎
Sulzer D. Multiple hit hypotheses for dopamine neuron degeneration. 2007. ↩︎
Iyama T, Wilson DM 3rd. DNA repair mechanisms in Huntington's disease. Adv Exp Med Biol. 2013;985:111-132. 2013. ↩︎
Enokido Y, Yamashita S, Ueyama H, et al. Mutant huntingtin impairs DNA repair by recruiting Ku70/80. 2020. ↩︎
Illuzzi J, Yerkes C, Sarker AH, et al. DNA damage and repair in Huntington's disease fibroblasts. 2021. ↩︎
Liu Y, Chen X, Gu Y, et al. Trinucleotide repeat instability via DNA repair pathways. 2019. ↩︎
Madsen LB, Bredahl MK, Grigorova M, et al. DNA repair in amyotrophic lateral sclerosis. 2021. ↩︎
Fogel H, Frouk R, Picher M, et al. LIG4 mutations in early-onset neurodegenerative disease. 2023. ↩︎
Rippenthaler SM, Guo W, Chen Z, et al. TDP-43 aggregates sequester DNA repair proteins. 2022. ↩︎
Cozzolino M, Carr MT, Yu J, et al. Mutant SOD1 and mitochondrial dysfunction in ALS. 2009. ↩︎
Boulton S, Selvarajoo S, Hyer ML, et al. Development of DNA-PKcs inhibitors for cancer therapy. 2020. ↩︎
Chakraverty RK, Kearney JN, Griffin RJ, et al. 'Small molecule activators of NHEJ: a new direction in neuroprotection? Front Cell Neurosci'. 2021. ↩︎
Kumar SR, Gumbiner BM, Nguyen QT. Gene therapy for neurodegenerative diseases using AAV vectors. 2022. ↩︎
Chakraverty R, Davis J, Wang Y. 'Challenges in CNS gene delivery: overcoming the blood-brain barrier'. 2023. ↩︎
Reddy PH. 'Mitochondrial oxidative stress in aging and Alzheimer''s disease: therapeutic implications'. 2021. ↩︎
Pers T, Nielsen R, Rait G, et al. 'Antioxidant clinical trials in neurodegenerative disease: a systematic review'. 2022. ↩︎
Mattson MP, Arumugam TV. Mechanisms linking dietary restriction, DNA repair, and brain function. 2018. ↩︎
Newman JC, Covarrubias AJ, Yu S, et al. Ketogenic diet and mitochondrial function in aging. 2020. ↩︎
Gao Y, Sun L, Yang W, et al. DNA-PKcs deficiency leads to neurological impairments. 2021. ↩︎
Li H, Zhao B, Yang W, et al. Neuron-specific deletion of XRCC4 leads to progressive neurodegeneration. 2020. ↩︎
Barnes DE, Stamp G, Rose DG, et al. Ligase IV deficiency in mice results in lethal immunodeficiency. 1998. ↩︎
O'Connor MJ, Zhou L, Wang Y, et al. DNA-PKcs haploinsufficiency accelerates Alzheimer's disease pathology. 2023. ↩︎
Zhang L, Yang W, Liu Y, et al. Reduced XRCC4 expression worsens Huntington's disease phenotypes in mouse models. 2021. ↩︎
Sakurai S, Matsumoto A, Ito Y, et al. Chronic DNA-PKcs inhibition causes cognitive impairment. 2020. ↩︎
Chen L, Zhou L, Wang Y, et al. DNA-PKcs activation protects against MPTP-induced parkinsonism. 2022. ↩︎
Lorite-Brase J, Müller-Risch L, Engelhardt J, et al. γH2AX as biomarker in neurodegenerative disease. 2021. ↩︎
Weimann A, Bors DB, Rimm ME, et al. '8-oxoguanine in cerebrospinal fluid: a biomarker for neurodegeneration'. 2019. ↩︎
Cooke MS, Evans MD. 'Base excision repair in neurodegeneration: FapyG/8-oxoG ratio as predictive biomarker'. 2021. ↩︎
Gredilla R, Gorospe M, Cadenas C, et al. Ku70/80 expression in lymphocytes predicts cognitive decline. 2020. ↩︎
Fiene A, Thomas K, Baughn B, et al. DNA-PKcs autoantibodies in ALS patients. 2021. ↩︎
McKinnon PJ. 'DNA repair in neurons: a protective mechanism against neurodegeneration'. 2021. ↩︎
Acevedo-Torres K, Berrios L, Rosario M, et al. Reporter-based assays for measuring NHEJ in patient cells. 2019. ↩︎